Attached files

file filename
EX-23.2 - EX-23.2 - Timber Pharmaceuticals, Inc.a17-24000_7ex23d2.htm
EX-5.1 - EX-5.1 - Timber Pharmaceuticals, Inc.a17-24000_7ex5d1.htm

 

As filed with the Securities and Exchange Commission on November 20, 2017

Registration No. 333-     

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

FORM S-1

 

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 


 

BIOPHARMX CORPORATION

(Exact name of registrant as specified in its charter)

 


 

Delaware

 

2834

 

59-3843182

(State or other jurisdiction of
incorporation or organization)

 

(Primary Standard Industrial
Classification Code Number)

 

(I.R.S. Employer
Identification Number)

 

1505 Adams Drive, Suite D

Menlo Park, California 94025

(650) 889-5020

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 


 

Anja Krammer

President

1505 Adams Drive, Suite D

Menlo Park, California 94025

(650) 889-5020

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

Copies to:

 

Robert Freedman, Esq.
Niki Fang, Esq.
Fenwick & West LLP
801 California Street
Mountain View, CA 94041
(650) 988-8500

 

Ivan K. Blumenthal, Esq.
Cliff M. Silverman, Esq.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo,
P.C.
Chrysler Center
666 Third Avenue
New York, NY 10017
(212) 935-3000

 


 

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

 

If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box.    o

 

If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.    x 333-221027

 

If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.    o

 

If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration number of the earlier effective registration statement for the same offering.    o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer

o

Accelerated filer

o

Non-accelerated filer

o  (Do not check if a smaller reporting company)

Smaller reporting company

x

 

 

Emerging growth company

o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.     o

 


 

Calculation of Registration Fee

 

 

 

 

 

 

 

Title of Each Class of
Securities to be Registered

 

Proposed Maximum
Aggregate Offering
Price(1)(2)

 

Amount of
Registration Fee(2)

 

Common Stock, $0.001 par value

 

$

1,025,000

(6)(7)

$

128

 

Pre-funded warrants to purchase shares of common stock

 

$

1,025,000

(6)(7)

$

128

 

Shares of common stock issuable upon exercise of pre-funded warrants(3)

 

 

 

Series A common warrants to purchase shares of common stock

 

$

1,025,000

 

$

128

 

Series B common warrants to purchase shares of common stock

 

$

1,025,000

 

$

128

 

Shares of common stock issuable upon exercise of Series A common warrants and Series B common warrants(3)

 

 

 

Representative’s warrant to purchase common stock(4)

 

$

20,500

 

$

3

 

Common stock underlying Representative’s warrant(3)

 

 

 

Total

 

$

3,095,500

 

$

387

(5)

(1)             Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(o) under the Securities Act of 1933, as amended.

 

(2)             Pursuant to Rule 416(a) under the Securities Act of 1933, as amended, this registration statement shall also cover an indeterminate number of shares that may be issued and resold resulting from stock splits, stock dividends or similar transactions.

 

(3)             No registration fee required pursuant to Rule 457(g) under the Securities Act of 1933, as amended.

 

(4)             Estimated solely for the purposes of calculating the registration fee pursuant to Rule 457(g) under the Securities Act of 1933, as amended. Represents warrants to purchase a number of shares of common stock equal to 2.0% of the common stock and pre-funded warrants (including the common stock issuable upon exercise of the pre-funded warrants) sold in this offering. The warrant is exercisable at a per share exercise price equal to the closing price of our common stock on the day prior to closing of this offering.

 

(5)             All of this amount was previously paid with the initial filing of the Registration Statement on Form S-1 (File No. 333-221027), which was declared effective on November 20, 2017.

 

(6)             The proposed additional maximum offering price of the common stock proposed to be sold in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any additional pre-funded warrants offered and sold in the offering, and as such the proposed additional aggregate maximum offering price of the common stock together with the pre-funded warrants (including the common stock issuable upon exercise of the pre-funded warrants), if any, is $1,025,000.

 

(7)             Based on the public offering price. The registrant previously registered securities at an aggregate offering price not to exceed $30,200,000 on a Registration Statement on Form S-1 (File No. 333-221027), which was declared effective on November 20, 2017. In accordance with Rule 462(b) promulgated under the Securities Act, an additional amount of securities having a proposed maximum aggregate offering price of $3,095,500 is hereby registered, which does not include the securities that the Registrant previously registered on the Registration Statement on Form S-1 (File No. 333-221027).

 


 

This Registration Statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(b) promulgated under the Securities Act.

 

 

 



 

EXPLANATORY NOTE AND INCORPORATION OF CERTAIN INFORMATION BY REFERENCE

 

This Registration Statement is being filed with the Securities and Exchange Commission, or Commission, pursuant to Rule 462(b) under the Securities Act of 1933, as amended. This Registration Statement relates to the public offering of securities of the Registrant contemplated by the Registration Statement on Form S-1 (File No. 333-221027), initially filed with the Commission by the Registrant on October 19, 2017, as amended, the “Prior Registration Statement”, and is being filed for the sole purpose of registering an increase in the maximum aggregate offering price of $3,095,500 of securities of the same class as were included in the Prior Registration Statement. The contents of the Prior Registration Statement, which was declared effective by the Commission on November 20, 2017, and all exhibits thereto are hereby incorporated by reference into this Registration Statement.

 

The required opinion and consents are listed on an Exhibit Index attached hereto and filed herewith.

 

EXHIBIT INDEX

 

Exhibit

 

 

 

Incorporated by Reference

 

Filed

 

Number

 

Exhibit Description

 

Form

 

File No.

 

Exhibit

 

Filing Date

 

Herewith

 

5.1

 

Opinion of Fenwick & West LLP

 

 

 

 

 

 

 

 

 

X

 

23.1

 

Consent of Fenwick & West LLP (contained in Exhibit 5.1)

 

 

 

 

 

 

 

 

 

X

 

23.2

 

Consent of BPM LLP, Independent Registered Public Accounting Firm

 

 

 

 

 

 

 

 

 

X

 

24.1

 

Power of Attorney

 

S-1

 

333-220127

 

24.1

 

10/19/2017

 

 

 

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Act, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Menlo Park, State of California, on this 20th day of November 2017.

 

 

BIOPHARMX CORPORATION

 

 

 

By:

/s/ ANJA KRAMMER

 

 

Anja Krammer

 

 

 

President

 

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

 

Name

 

Title

 

Date

 

 

 

 

 

/s/ ANJA KRAMMER

 

President and Director (Principal Executive Officer)

 

November 20, 2017

Anja Krammer

 

 

 

 

 

 

 

 

/s/ GREG KITCHENER

 

Chief Financial Officer (Principal Financial and Accounting Officer)

 

November 20, 2017

Greg Kitchener

 

 

 

 

 

 

 

 

*

 

Director

 

November 20, 2017

Michael Hubbard

 

 

 

 

 

 

 

 

 

*

 

Director

 

November 20, 2017

Stephen Morlock

 

 

 

 

 

 

 

 

 

*

 

Director

 

November 20, 2017

C. Gregory Vontz

 

 

 

 

 

*                 Pursuant to Power of Attorney

 

By:

/s/ Anja Krammer

 

 

Anja Krammer

 

 

Attorney-in-Fact

 

 

3